Autopsy report · NCT04941183

Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients

“the emergence of the omicron variant of COVID-19 lead to insufficient enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 2 months before it stopped.
• 52 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Neutrolis

Sponsor type

Industry

Conditions

Covid19

Interventions

NTR-441; Placebo

Participants

52

Sites

4

Countries

Austria, Ukraine

Trials that died the same way

• Novel SARS-CoV-2 Point-of-care Testing
  “failure in enrolling eligible subjects during COVID-19 outbreaks” (68% match in meaning)
• Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate
  “Covid 19 Pandemic - Unable to enroll patients” (67% match in meaning)
• Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
  “Enrollment was affected due to the COVID-19 pandemic” (67% match in meaning)
• The Interrogation of the Cardiomyopathy of Chronic Kidney Disease With advancEd caRdiac Imaging
  “COVID-19 pandemic; pre-pandemic recruitment sufficient for scientific validity” (67% match in meaning)
• A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer
  “COVID-19 pandemic, unable to enroll participants” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.